CY002-243-1

**CY002-243-1** is a highly potent, degradable *molecular glue* designed for targeted cancer therapy. Its unique mechanism involves mediating interactions between **phosphodiesterase 3A (PDE3A)** and **schlafen family member 12 (SLFN12)**, leading to the inhibition of these proteins. The drug acts by facilitating the proximity-induced degradation or modulation of PDE3A and SLFN12, disrupting signaling pathways essential for cancer cell survival and proliferation. CY002-243-1 is being developed primarily for neoplastic diseases, including multiple carcinomas, digestive system disorders, and metabolic disease indications. Preclinical profiling has highlighted its potential as a targeted therapy for various cancer subtypes[1][2][9].

Brand names

CY002-243-1CY-002-243-1CY 002-243-1

Other names

CY002-243-1CY-002-243-1CY 002-243-1CY002CY-002CY 002